Cargando…

miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy

Background: LDH (lactate dehydrogenase), AFP (alpha-fetoprotein) and β-HCG (human chorionic gonadotropin) are used in diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. Our aim was to investigate the association between levels of miR-371a-3p, miR-373-3p and miR-367-3p and clinic...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosas Plaza, Ximena, van Agthoven, Ton, Meijer, Coby, van Vugt, Marcel A. T. M., de Jong, Steven, Gietema, Jourik A., Looijenga, Leendert H. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830325/
https://www.ncbi.nlm.nih.gov/pubmed/31597402
http://dx.doi.org/10.3390/cells8101221
_version_ 1783465757990977536
author Rosas Plaza, Ximena
van Agthoven, Ton
Meijer, Coby
van Vugt, Marcel A. T. M.
de Jong, Steven
Gietema, Jourik A.
Looijenga, Leendert H. J.
author_facet Rosas Plaza, Ximena
van Agthoven, Ton
Meijer, Coby
van Vugt, Marcel A. T. M.
de Jong, Steven
Gietema, Jourik A.
Looijenga, Leendert H. J.
author_sort Rosas Plaza, Ximena
collection PubMed
description Background: LDH (lactate dehydrogenase), AFP (alpha-fetoprotein) and β-HCG (human chorionic gonadotropin) are used in diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. Our aim was to investigate the association between levels of miR-371a-3p, miR-373-3p and miR-367-3p and clinical features in metastatic TGCC. Methods: relative levels of miR-371a-3p, miR-373-3p and miR-367-3p were evaluated in serum of metastatic TGCC patients. A prospectively included and a retrospectively selected cohort were studied (total patient number = 109). Blood samples were drawn at start of chemotherapy and during follow-up. Serum microRNA (miR) levels were determined using the ampTSmiR test. Results: at start of chemotherapy, miR-371a-3p, miR-373-3p and miR-367-3p levels were positively correlated to LDH. The median level of these miRs was higher in patients who developed a relapse after complete biochemical remission (n = 34) than in those who had complete durable remission (n = 60). Higher levels of miR-367-3p were found in patients with refractory disease (n = 15) compared to those who had complete response. miR levels decreased during the first week of chemotherapy in patients with complete response and stayed below threshold after one year of treatment. Conclusion: high miR levels at start of chemotherapy are associated with worse clinical outcome and can assist in early diagnosing of relapses.
format Online
Article
Text
id pubmed-6830325
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-68303252019-11-20 miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy Rosas Plaza, Ximena van Agthoven, Ton Meijer, Coby van Vugt, Marcel A. T. M. de Jong, Steven Gietema, Jourik A. Looijenga, Leendert H. J. Cells Article Background: LDH (lactate dehydrogenase), AFP (alpha-fetoprotein) and β-HCG (human chorionic gonadotropin) are used in diagnosis and follow-up of testicular germ cell cancer (TGCC) patients. Our aim was to investigate the association between levels of miR-371a-3p, miR-373-3p and miR-367-3p and clinical features in metastatic TGCC. Methods: relative levels of miR-371a-3p, miR-373-3p and miR-367-3p were evaluated in serum of metastatic TGCC patients. A prospectively included and a retrospectively selected cohort were studied (total patient number = 109). Blood samples were drawn at start of chemotherapy and during follow-up. Serum microRNA (miR) levels were determined using the ampTSmiR test. Results: at start of chemotherapy, miR-371a-3p, miR-373-3p and miR-367-3p levels were positively correlated to LDH. The median level of these miRs was higher in patients who developed a relapse after complete biochemical remission (n = 34) than in those who had complete durable remission (n = 60). Higher levels of miR-367-3p were found in patients with refractory disease (n = 15) compared to those who had complete response. miR levels decreased during the first week of chemotherapy in patients with complete response and stayed below threshold after one year of treatment. Conclusion: high miR levels at start of chemotherapy are associated with worse clinical outcome and can assist in early diagnosing of relapses. MDPI 2019-10-08 /pmc/articles/PMC6830325/ /pubmed/31597402 http://dx.doi.org/10.3390/cells8101221 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rosas Plaza, Ximena
van Agthoven, Ton
Meijer, Coby
van Vugt, Marcel A. T. M.
de Jong, Steven
Gietema, Jourik A.
Looijenga, Leendert H. J.
miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy
title miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy
title_full miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy
title_fullStr miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy
title_full_unstemmed miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy
title_short miR-371a-3p, miR-373-3p and miR-367-3p as Serum Biomarkers in Metastatic Testicular Germ Cell Cancers Before, During and After Chemotherapy
title_sort mir-371a-3p, mir-373-3p and mir-367-3p as serum biomarkers in metastatic testicular germ cell cancers before, during and after chemotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6830325/
https://www.ncbi.nlm.nih.gov/pubmed/31597402
http://dx.doi.org/10.3390/cells8101221
work_keys_str_mv AT rosasplazaximena mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy
AT vanagthoventon mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy
AT meijercoby mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy
AT vanvugtmarcelatm mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy
AT dejongsteven mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy
AT gietemajourika mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy
AT looijengaleenderthj mir371a3pmir3733pandmir3673passerumbiomarkersinmetastatictesticulargermcellcancersbeforeduringandafterchemotherapy